BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 9857097)

  • 21. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
    Khan TH; Eno-Amooquaye EA; Searle F; Browne PJ; Osborn HM; Burke PJ
    J Med Chem; 1999 Mar; 42(6):951-6. PubMed ID: 10090777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
    Springer CJ; Niculescu-Duvaz I; Pedley RB
    J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
    Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
    Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
    Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
    J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
    Friedlos F; Denny WA; Palmer BD; Springer CJ
    J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
    Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
    Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
    Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
    Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
    Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
    Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
    Henderson ND; Plumb JA; Robins DJ; Workman P
    Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
    Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
    Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect.
    Stribbling SM; Friedlos F; Martin J; Davies L; Spooner RA; Marais R; Springer CJ
    Hum Gene Ther; 2000 Jan; 11(2):285-92. PubMed ID: 10680842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
    Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
    Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
    Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiosynthesis of 4-[(2-chloroethyl)(2-[(11)C]ethyl)amino]-phenoxycarbonyl-l-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography.
    Malik N; Luthra SK; Burke P; Price PM; Aboagye EO; Latigo J; Zhao Y; Brady F
    Appl Radiat Isot; 2004 Jun; 60(6):825-34. PubMed ID: 15110346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
    Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.